TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30521653

Group type: EXPERIMENTAL
Intervention: Antrostomy height of 4 mm (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antrostomy height of 8 mm (Group B)
Number of subjects: 24
Study: 28054261

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 26458774

Group type: EXPERIMENTAL
Intervention: Lobeglitazone monotherapy
Number of subjects: 0
Study: 23591780

Group type: EXPERIMENTAL
Intervention: Bitopertin (RG1678)
Number of subjects: 0
Study: 21241447

Group type: EXPERIMENTAL
Intervention: Laughter therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control
Number of subjects: 109
Study: 19123484

Group type: EXPERIMENTAL
Intervention: Video Feedback (VF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No Video Feedback (Control)
Number of subjects: 36
Study: 17225002

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 48
Study: 15115831

Group type: EXPERIMENTAL
Intervention: Triple-nucleoside group (zidovudine-lamivudine-abacavir)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Efavirenz groups (zidovudine-lamivudine plus efavirenz and zidovudine-lamivudine-abacavir plus efavirenz)
Number of subjects: 1147
Study: 10828749

Group type: EXPERIMENTAL
Intervention: Non-invasive H. pylori testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eradication of H. pylori infection
Number of subjects: 0
Study: 8636172

Group type: EXPERIMENTAL
Intervention: Cemented unipolar prosthesis (Thompson)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cemented bipolar prosthesis (Monk)
Number of subjects: 0
Study: 1568631

Group type: EXPERIMENTAL
Intervention: 1 g i.v. cefotaxime
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 1.2 g amoxicillin plus clavulanic acid
Number of subjects: 119
Study: 4068610

Group type: COMPARATOR
Intervention: Antacid (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: H2 blocker (group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments (group A and B)
Number of subjects: 24
Study: 31722697

Group type: EXPERIMENTAL
Intervention: Customized arch support orthosis (CASO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Orthotic heel lift (HL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Without orthotics
Number of subjects: 12
Study: 29417495

Group type: EXPERIMENTAL
Intervention: Continuous Care Intervention (CCI)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 349
Study: 24387078

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily combined with sildenafil 50 mg as needed
Number of subjects: 180

Group type: COMPARATOR
Intervention: Tadalafil 5 mg once daily
Number of subjects: 180
Study: 23905949

Group type: EXPERIMENTAL
Intervention: Unilateral percutaneous pedicle screw fixation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Bilateral percutaneous pedicle screw fixation
Number of subjects: 53
Study: 21964220

Group type: EXPERIMENTAL
Intervention: Breast massage (two 30-minute sessions within 10 days postpartum)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 60
Study: 18248281

Group type: EXPERIMENTAL
Intervention: CHARITE Artificial Disc
Number of subjects: 0

Group type: COMPARATOR
Intervention: BAK devices
Number of subjects: 0
Study: 16569261

Group type: COMPARATOR
Intervention: Cefepime (C group, 20 patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cefepime with amikacin (C-A group, 19 patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cefepime with levofloxacin (C-L group, 20 patients)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cefepime (C group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cefepime with amikacin (C-A group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cefepime with levofloxacin (C-L group)
Number of subjects: 74
Study: 15041274

Group type: EXPERIMENTAL
Intervention: Rapidpoint ENOX
Number of subjects: 166
Study: 11025707

Group type: EXPERIMENTAL
Intervention: CaverMap group (nerve sparing assisted by the CaverMap Surgical Aid)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional nerve sparing group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CaverMap group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CaverMap group (bilateral response)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CaverMap group (unilateral response)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CaverMap group (no response)
Number of subjects: 61
Study: 8624266

Group type: EXPERIMENTAL
Intervention: Supportive calcitonin
Number of subjects: 36
Study: 1375731

Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program intervention (combining early child development and family support services with pediatric follow-up)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program intervention
Number of subjects: 0
Study: 3919604

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms b.d.)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Disodium Cromoglycate (DSCG) (5.2 mg 5 times daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 43
Study: 29961573

Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antagonist)
Number of subjects: 117
Study: 29374714

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: N3 patients with metastases to two or more N3 regions
Number of subjects: 144
Study: 26708475

Group type: EXPERIMENTAL
Intervention: Day care management of NVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient management of NVP
Number of subjects: 0
Study: 23949963

Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 μg
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Umeclidinium 125 μg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 22134669

Group type: EXPERIMENTAL
Intervention: Cauterization of the inferior turbinate artery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cauterization negative group (control)
Number of subjects: 60
Study: 20180611

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Proton Pump Inhibitors (PPIs)
Number of subjects: 0
Study: 18797405

Group type: EXPERIMENTAL
Intervention: TMZ+training (TT), n=30, received TMZ 20 mg three times daily for 8 weeks and underwent exercise training at 60% of oxygen uptake at peak, three times a week for 8 weeks.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: TMZ (n=30), received TMZ 20 mg three times daily for 8 weeks without exercise training.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Exercise (E, n=30), completed exercise training without receiving TMZ.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (C, n=26), neither exercised nor received TMZ.
Number of subjects: 116
Study: 16170062

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 1

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 1
Study: 12958567

Group type: EXPERIMENTAL
Intervention: montelukast
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 11009863

Group type: EXPERIMENTAL
Intervention: $20 prepayment
Number of subjects: 0

Group type: COMPARATOR
Intervention: $20 postpayment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: $25 postpayment
Number of subjects: 0
Study: 8430276

Group type: EXPERIMENTAL
Intervention: Duodenal perfusion with pancreaticobiliary juice at a rate of 5 ml/min for 10 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline at a rate of 5 ml/min for 10 min
Number of subjects: 8
Study: 2441643

Group type: EXPERIMENTAL
Intervention: Lactose challenge
Number of subjects: 68

Group type: COMPARATOR
Intervention: Milk challenge
Number of subjects: 68
Study: 31997509

Group type: EXPERIMENTAL
Intervention: 140 mg Livergol capsule per day for 30 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Starch-containing capsule as a placebo once a day for 30 days
Number of subjects: 74
Study: 25895509

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 27819257

Group type: EXPERIMENTAL
Intervention: Preemptive antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empirical antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Number of subjects: 0
Study: 26088044

Group type: EXPERIMENTAL
Intervention: Information (child and carer received information on the health benefits of water)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Placement (information + free small bottles of still water delivered at home)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Placement + Community (child and caregiver engaged in an online community forum)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Community (engagement in an online community forum)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study: 24304990

Group type: COMPARATOR
Intervention: Insulin (group-A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Metformin (group-B)
Number of subjects: 68
Study: 20708850

Group type: EXPERIMENTAL
Intervention: Plan_4D (adaptive radiotherapy)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Plan_3D (conventional radiotherapy)
Number of subjects: 13
Study: 19484982

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) by nasal spray
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inhaling
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nasal spray-inhaling combined administration
Number of subjects: 90
Study: 16887471

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 1500 mg day(‐1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 1000 mg day(‐1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 500 mg every 8 h
Number of subjects: 26
Study: 15646945

Group type: EXPERIMENTAL
Intervention: Sonic brushing
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Manual brushing and daily flossing
Number of subjects: 47

Group type: COMPARATOR
Intervention: Manual brushing only
Number of subjects: 47

Group type: COMPARATOR
Intervention: Rotational oscillation brushing
Number of subjects: 47

Group type: COMPARATOR
Intervention: Electric brushing using a rotational oscillation toothbrush
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Electric brushing using a sonic toothbrush
Number of subjects: 47
Study: 11298072

Group type: EXPERIMENTAL
Intervention: Clinical pharmacy intervention involving development of professional relationships, nurse education on medication issues, and individualized medication reviews
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Control group (standard care in nursing homes)
Number of subjects: 3230
Study: 10471546

Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis for pregnant women
Number of subjects: 0
Study: 7592245

Group type: EXPERIMENTAL
Intervention: Asthmatic patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 15
Study: 2547139

Group type: EXPERIMENTAL
Intervention: 2.5 mg piperazine oestrone sulphate/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 2.0 mg oestradiol valerate/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10.0 mg oestriol/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Combination with levonorgestrel (LNG) 250 micrograms/day
Number of subjects: 7
Study: 1252278

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0
Study: 31599031

Group type: EXPERIMENTAL
Intervention: Immune-related genes identified and characterized from P. puparum genome and transcriptome databases.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative analysis of immune-related genes from seven insect species.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Developmental expression profiles of immune genes verified by quantitative polymerase chain reaction.
Number of subjects: 0
Study: 31839957

Group type: EXPERIMENTAL
Intervention: 3-day low-fibre diet
Number of subjects: 412

Group type: COMPARATOR
Intervention: 1-day low-fibre diet
Number of subjects: 412
Study: 27190095

Group type: EXPERIMENTAL
Intervention: Biolimus-A9-coated stent (BA9-DCS)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 659
Study: 26093636

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: IPS enhanced with cognitive remediation and work-related social skills training
Number of subjects: 750

Group type: COMPARATOR
Intervention: Service as usual
Number of subjects: 750
Study: 23187043

Group type: EXPERIMENTAL
Intervention: Body weight‐supported progressive high‐intensity locomotor training (8-week program, 3 × 1h/week)
Number of subjects: 13
Study: 20889387

Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin injection
Number of subjects: 0
Study: 19084439

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 0.33 microg kg(‐1)h(‐1) infusion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide
Number of subjects: 44
Study: 16798161

Group type: EXPERIMENTAL
Intervention: Vacuum Tube (VT) method
Number of subjects: 64

Group type: COMPARATOR
Intervention: Syringe Needle (SN) method
Number of subjects: 64
Study: 12548313

Group type: EXPERIMENTAL
Intervention: Polyunsaturated spread with 2 g of plant sterols
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polyunsaturated spread without plant sterols
Number of subjects: 50
Study: 11853616

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 128
Study: 9316514

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy followed by additional balloon angioplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balloon angioplasty alone
Number of subjects: 50
Study: 8296077

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/day (n = 27)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ranitidine 150 mg/day (n = 29)
Number of subjects: 56
Study: 3570053

Group type: COMPARATOR
Intervention: Irradiation alone (1000 cGy whole pelvis, additional 4000 cGy to the parametria, two intracavitary insertions for 7500 mgh)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Preoperative radiation and surgery (2000 cGy whole pelvis, one intracavitary insertion for 5000-6000 mgh followed by radical hysterectomy)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Preoperative radiation and surgery
Number of subjects: 118
Study: 31267688

Group type: EXPERIMENTAL
Intervention: Nurse-administered intraocular injections
Number of subjects: 342

Group type: COMPARATOR
Intervention: Physician-administered intraocular injections
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Nurse-administered injections
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 342
Study: 30372645

Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) contraceptive implant
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 103
Study: 27498280

Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography using start systolic index (SSI)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography using peak longitudinal displacement (PLD)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Visual assessment of apical rocking (AR) by expert readers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Visual assessment of apical rocking (AR) by novice readers
Number of subjects: 125
Study: 24835329

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 82

Group type: COMPARATOR
Intervention: Embedded struts
Number of subjects: 82

Group type: COMPARATOR
Intervention: Struts with tissue prolapse
Number of subjects: 82
Study: 22403884

Group type: EXPERIMENTAL
Intervention: Computer assisted navigation (navigation group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional technique (traditional group)
Number of subjects: 92
Study: 20624648

Group type: EXPERIMENTAL
Intervention: Wild-type varicella zoster virus infection (WTVZV)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: WTVZV infection at age 0 to 8 years
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: WTVZV infection at age 8 to 18 years
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: WTVZV
Number of subjects: 678
Study: 18248651

Group type: EXPERIMENTAL
Intervention: Evening GH and/or morning hydrocortisone treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omission of evening GH and/or morning hydrocortisone treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Treatment with GH
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omission of GH treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omission of GH treatment in PHDC+ patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omission of GH treatment in patients with PHDC-
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Treatment and meals omission
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low BMI and young age
Number of subjects: 20
Study: 15684164

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 mug vaginally every 6 hours, most frequent regimen)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Misoprostol (in women with prior cesarean delivery)
Number of subjects: 101
Study: 12352923

Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chronic allograft nephropathy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Detection of human herpesvirus 6 DNA
Number of subjects: 37
Study: 10473080

Group type: EXPERIMENTAL
Intervention: irinotecan (CPT‐11; 200 mg/m2) as a 90‐min i.v. infusion followed by cisplatin (CDDP; 80 mg/m2) as a 3‐h i.v. infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: irinotecan (CPT‐11)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP)
Number of subjects: 11
Study: 8904391

Group type: EXPERIMENTAL
Intervention: Public health nursing services
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Public health nursing services and physician contacts
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Multidisciplinary approaches to prenatal care
Number of subjects: 1223
Study: 1667474

Group type: EXPERIMENTAL
Intervention: Anticalculus dentifrice containing 1.3% soluble pyrophosphate and 1.5% Gantrez copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride in a silica base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customary oral hygiene procedures
Number of subjects: 0
Study: 7047469

Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31273283

Group type: EXPERIMENTAL
Intervention: Modafinil treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study: 28112575

Group type: EXPERIMENTAL
Intervention: Clinical care group
Number of subjects: 320

Group type: COMPARATOR
Intervention: International Warfarin Pharmacogenetic Consortium algorithm
Number of subjects: 320

Group type: COMPARATOR
Intervention: Taiwan algorithm
Number of subjects: 320
Study: 26100229

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2, administered on day 1 every 21 days)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Volasertib with Pemetrexed
Number of subjects: 143

Group type: COMPARATOR
Intervention: Volasertib (300 mg, administered on day 1 every 21 days)
Number of subjects: 143
Study: 25146063

Group type: EXPERIMENTAL
Intervention: Exercise training and music therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pharmacotherapy (antidepressant drugs)
Number of subjects: 24
Study: 21148540

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear bone marrow cells (n = 69)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear peripheral blood cells (n = 66)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard therapy (n = 65)
Number of subjects: 200
Study: 19300145

Group type: EXPERIMENTAL
Intervention: High concentration botulinum toxin A (100 U/ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low concentration botulinum toxin A (10 U/ml)
Number of subjects: 16
Study: 17913697

Group type: EXPERIMENTAL
Intervention: Setting A (70/65 bpm)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Setting B (70/Off)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Setting C (80/65 bpm)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Baseline pacing (60 bpm/Off)
Number of subjects: 99
Study: 14988255

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-fat meal and glucose alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-fat meal plus glucose
Number of subjects: 50
Study: 11672451

Group type: EXPERIMENTAL
Intervention: Hypoxic training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 32
Study: 9133941

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin 200 IU daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8265106

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3631942

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cefotaxime (2 g)
Number of subjects: 6